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ABSTRACT
Objective: According to unsatisfactory therapeutic results in patients with chronically recurrent
vaginal candidosis, we investigated if immunologic patient factors could be found and treated.
Methods: In 42 women with chronically recurrent and 20 women with acute Candida albicans
vulvovaginitis, as well as 14 women with C. glabrata vaginitis, the following investigations were
carried out: identification of yeast .species; quantification ofT lymphocytes and their subpopulations
in sera; proliferation tests of T lymphocytes in vitro; treatment of 18 patients with chronically
recurrent vaginal candidosis with the synthetic T-lymphocyte- stimulator thymopentin; and, finally,
control of the above-mentioned parameters in the clinical course.
Results:Women with C. albicans vulvovaginitis showed fewerT lymphocytes and subpopulations
in the peripheral blood than healthy women. Only the number of non-specific killer (NK) cells,
however, was significantly lower in cases of acute C. albicans vulvovaginitis. In women with C.
glabrata vaginitis, the number ofT lymphocytes in the blood was within the normal range. In vitro
proliferation tests using mitogens, bacterial antigens, and commercially available candida antigens
with and without addition of thymopentin were carried out on the T lymphocytes of women with
chronically recurrent C. albicans vulvovaginitis. These tests revealed no significant differences
compared with the other patients with C. albicans infections. The patients were treated with thymo-
pentin. Those women who revealed an increase of initially low numbers ofT-helper cells recovered
from vaginal candidosis after thymopentin treatment.
Conclusions: The peripheralT lymphocytes may be diminished in patients with chronically recur-
rent C. albicans vaginitis, and immunologic treatment can reduce the relapse rate.
(C) 1997 Wiley-Liss, Inc.
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wing to particular pathogenic features, the fac-
ultatively pathogenic yeast Candida albicans is
more likely to cause an infection in predisposed
persons than other candida species are. These
pathogenic features 1,z include the utilization of car-
bohydrates and proteins, high-temperature and pH
tolerance, occurrence in the guise of blastospores
and pseudomycelia, formation of proteases and
phospholipases, utilization of the host’s ferrum by
means of siderophores, capability of adherence to
other epithelia, molecular mimicry to deceive im-
munocells, phenotype "switching," and possible
synergism with bacteria. The clinical manifestations
of vulvovaginal candidosis have been illustrated in
a nomenclature recommendation. Accordingly, C.
glabrata vaginitis is usually associated with fewer
clinical symptoms ofvaginitis than C. albicans vulvo-
vaginitis is. Concerning the clinical signs, we do
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not agree with the opinion of Redondo-Lopez et
al. who stated that the clinical picture of Torulopsis
(C. glabrata) vulvovaginitis was not different from
the classical presentation of candida vulvovaginitis.
The rate of recovery from acute vaginal candidosis
is 75-80% after 4 weeks. In the case of chronically
recurrent vulvovaginal candidosis (at least 4 epi-
sodes per year), the rate is only 50% despite antimy-
cotic treatment carried out over several months.
Proceeding from these facts, we carried out the
following investigations to see if immunologic defi-
ciencies in women with acute or chronic C. albicans
or C. glabrata vulvovaginitis could be measured pe-
ripherally and possibly eliminated. Some results of
our investigations have already been published,
specifically those concerning local immunity.9,1
SUBJECTS AND METHODS
Identification of Yeast Species
Vaginal secretions were collected with a speculum
during the vaginal examination and placed on Petri
plates containing Sabouraud glucose 2% agar. The
specimen was incubated for at least 2 days at 28C.
A positive culture was further differentiated by
means of rice-extract agar to identify C. albicans by
chlamydospores and other species by additional API
20C auxanogram (Bio M6rieux, Marcy-l’Etoile,
France).
washed again. The pellet was fixed with 0.02%
formaldehyde in phosphate buffered saline (PBS)
and the sample was then run through the flowcytom-
eter (Ortho, Raritan, NJ).
Proliferation Tests In Vitro
The lymphocyte proliferation assay was performed
on 96-well microplates (Greiner, Germany). For
stimulation of the 75-100 10 cells, candida anti-
gen (Pasteur) and the mitogens phytohemaggluti-
nin (PHA) concanavalin (Con) A, and pokeweed as
well as tuberculin and tetanus antigen were used.
All tests were done in several dilutions of the anti-
gens and quadruplets. Sixteen hours before harvest-
ing, 0.5 IxCi of3H-thymidine (Amersham, Arlington
Heights, IL) was added. On the fifth day, the cells
were collected on filters (Titertech cell harvester)
and the radioactivity was measured in an LS 7000
Beckmann scintillation counter. An index for the
results was used from the mean values (quadru-
plets) in counts per minute (cpm) of the experi,
ment, e.g., candida 1:40 and thymopentin added,
compared with the mean values of 12 not-stimu-
lated probes without antigen or mitogen.
Thymopentin was added in concentrations of
10,000 to 0.01 ng/ml. As an example of one index,
the result for candida 1:40 was 24,000 cpm, control
800 cpm, index 30.
Quantification of T Lymphocytes
A sample ofvenous blood was taken with a heparin-
ized syringe from each patient prior to any treat-
ment. A sample of heparinized blood was also taken
during and after treatment.
The peripheral blood was diluted with an equal
volume of RPMI 1640 and layered over Fiquol-
Hypaque. The preparation was centrifuged at 400g
for 30 min to allow density separation of the leuko-
cytes. The layer containing the lymphocytes was
harvested and washed. The cells were resuspended
at a cell density of approximately 10 cells/ml. An
aliquot of 50 1 of this suspension was added to
each of 7 tubes and incubated with the monoclonal
antibodies against CD4, CD8, CD 16, CD 19, HLA-
DR, CDllb, and an isotopic control antigen (Bec-
ton Dickinson, Mountain View, CA) for 30 min.
Thereafter, the cells were washed and a sheep anti-
mouse FAB fragment, conjugated with fluoroiso-
thiocyanate, was added. After incubation with the
fluorescent antibody for 30 min, the cells were
Clinical Follow-Up During and After
Thymopentin (Timunox 100, Cilag GmbH,
Sulzbach, Germany) Therapy
The data of 17 of the 18 otherwise healthy women
presenting with chronically recurrent vaginal can-
didosis were subdivided in one group of data ob-
tained 30 days before thymopentin therapy and an-
other group obtained 80 days during and after
thymopentin therapy. Thymopentin was injected
subcutaneously in dosages of 100 mg in the upper
arm twice a week for 10-15 injections. After observ-
ing that 15 injections did not raise the T lympho-
cytes more than 10 and considering the high costs
of this therapy, we injected only 10 times. Simulta-
neously, each patient was treated with one 500-mg
clotrimazole vaginal tablet.
The average values ofT lymphocytes and sub-
populations were calculated as mean values be-
tween a first value at the beginning of therapy and
a second value at the end of the course of injections.
The relapse rate of vaginal candidosis was noted
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TABLE I. Average values of peripheral immunocells in women with and without vaginal mycosis
Immunocells ( 106/ml)
Healthy women Acute
(N ) (N 0)
C. albicans
vulvovaginitis C. glabrata
Chronic vaginitis
(N 4) (N 4)
Lyrnphocytes (total) 2.05 +/-0.69
T lymphocytes 1.41 +/- 0.49
Precursors 0.22 +/- 0.14
T suppressor cytotoxic cells 0.57 +/-0.27
T helper cells 0.83 +/-0.23
B cells 0.19 +/- 0.07
HLA-DR-carrying cells 0.41 +/- 0.16
NK cells 0.61 +/- 0.32
1.94 1.88 2.21
I. 18 1.25 1.43
0.21 0.25 0.29
0.50 0.48 0.51
0.76 0.77 0.89
0.16 0.19 0.21
0.42 0.42 0.46
0.35* 0.4 I** 0.44***
*P 0.01.
**P- 0.06.
***P 0.14.
over a period of at least 6 months determined by
complaints and clinical signs as well as wet-mount
preparations and mycologic cultures of the vaginal
secretions about every 4 weeks.
A cure or reduction of the relapse rate was de-
fined as being without symptoms of vulvovaginal
candidosis for at least 5 months in a period of 6
months after the end of therapy.
RESULTS
Vaginal C. glabrata Vaginitis
The number of T-lymphocyte populations did not
differ significantly from the values found in healthy
women. In fact, the number of natural killer (NK)
cells was conspicuously lower.
Vaginal C. albicans Vulvovaginitis
Only the NK cell count in the blood was signifi-
cantly lower in acute cases compared with healthy
women, while all other peripheral immunocells re-
vealed no significant changes.
Chronically Recurrent C. albicans Vulvovaginitis
With these women, the peripheral NK cell count
was less significantly lower in comparison with
healthy women. These results are summarized in
Table 1.
Proliferation Tests In Vitro
In the 16 women with chronically recurrent C. albi-
cans vulvovaginitis, only 5 cases revealed a signifi-
cant and 3 cases a weak reaction to candida antigen
which, in initial tests, carried out with different
commercial and some homologue candida antigens
had been particularly stimulating.
11 Therefore, fur-
ther comparative proliferation tests were carried
out.
Thus, 3 women with acute and 8 women with
chronically recurrent C. albicans vaginitis as well as 1
woman with C. glabrata vaginitis could be compared
with 6 healthy women. The lymphocytes showed
a good reaction to mitogens in all women. However,
the reaction was better in the healthy women. The
different antigen stimulants showed lower single
and average values of indices. To see if patients
more frequently showed a weak reaction to candida
antigen or additional thymopentin stimulation than
healthy women, we defined a weak proliferate T-
lymphocyte reaction as a lower limit of the corres-
ponding index (3 or 2). However, we could not make
a conclusion from the present results (Table 2).
Results In Vivo During and After Thymopentin
Therapy in Women Presenting With
Chronically Recurrent C. albicans Vulvovaginitis
On average, the treatment with thymopentin re-
suited only in a low mean increase oft lymphocytes
and B cells, while the number of T-helper cells, T-
suppressor cytotoxic cells, and NK cells decreased,
which seem contradictory. An individual consider-
ation of the values of each patient by means of an
index is more revealing. This index was defined
by noting down the number and increase of the
respective immunocells before and after treatment
of each patient. It revealed a correlation between
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TABLE 2. Proliferation tests in vitro: Distribution of weak proliferations (index values) within various
patient groups
Candida
Mitogens Tetanus Tuberculin (index <=2)
(index <=3) (index _-<2) (index -<2) 1:5 1"40
Candida +
thymopentin
(index <=2)
1"5 1"40
Chronically recurrent C. albicans vaginitis (N 8) 0/8
Acute C. albicans vulvovaginitis (N 3) 2/3
C. glabrata vaginitis (N I) 0/I
Healthy women (N 6) 0/6
2/8 5/8 5/8 4/8 5/7 5/7
0/3 2/3 3/3 0/3 3/3 2/3
0/I I/I I/I 0/I 0/I 0/I
I/6 3/6 4/6 3/6 4/6 3/6
T-Lymphocytes
helper cells
Supp.- zyt.-T- ell
B cells
Normal Range
Duration of therapy ( o0/)
O o
Fig. I. Mean values of defense cells before and after treatment with thymopentin, grouped in
patients with (---) and without() successful therapy. Supp.-zyt. suppressor-cytotoxic.
a decreasing index and unsuccessful therapy and
vice versa. This trend was also suggested by the
average values of all women with and without suc-
cessful therapy. The changes often occurred within
the (lower) normal limits. A graphic representation
of the development, however, also revealed differ-
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Fig. 2. Clinical course: average values of the helper cells of (o) 10 non-cured patients and () 8
cured patients before and after irnmunostimulation with thymopentin.
ences between patients with and without cure (Fig.
1). In women who were cured, the average values
of T-helper cells were low, primarily within the
lower normal range, and slightly increased subse-
quent to therapy. In the case of unsuccessful ther-
apy, the normal average values of T-helper cells,
despite thymopentin injection, primarily decreased
within the first or 2 weeks, returning to the initial
values after about 4 weeks (Fig. 2).
Clinical Results After Thymopentin Therapy
In all, 18 women were treated with adjuvant thymo-
pentin. Sixteen of these patients suffered from
chronically recurrent vaginal candidosis, of whom
15 were caused by C. albicans and was caused by
C. brusd. One patient could not be evaluated be-
cause of no data. The 18th patient had allegedly
suffered from vaginal infection caused by C. glabrata
for 9 years; however, C. albicans was also demonstra-
ble on one occasion.
Before therapy, 16 women suffering from typical
vaginal candidosis for an average of 3.9 years were
evaluable. In 9 cases, the number ofT lymphocytes
before therapy was within or under the lower normal
range. In 6 of these patients, thymopentin treat-
ment resulted in a cessation of relapses, which was
defined as being without symptoms of vulvovaginal
candidosis for at least 5 of 6 months. Of the re-
maining 7 women who, before therapy, showed nor-
mal numbers ofT cells, only patient was treated
successfully, while the other 6 suffered from re-
lapses as before. The patient with C. glabrata vagini-
tis had normal values ofT lymphocytes before and
after the treatment; however, her therapy was not
successful.
DISCUSSION
Cellular Defense in Vaginal Mycoses
On average, the women with acute and chronically
recurrent vaginal candidosismfrequently with the
normal range of values--had fewer T lymphocytes,
fewer T-helper cells, fewer NK cells, and fewer B
cells than healthy women. Numerous references
point to the significance of cellular defense in the
case of candida infection, lz-19
The association of slightly lowered T-helper
cells with vaginal candidosis was proven in a group
ofimmune-suppressed patients. NK cells and a vari-
ety ofcytokines both seem to play their parts, appar-
ently in the defense against C. albicans as well.z
Phagocytosis may vary, however, depending on the
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yeast species, zl strain properties,zz or protease ac-
tivity,z3
Vaginal candidosis seems to lead to frequent
blocking of defense cell activity, a phenomenon
that was also shown in other investigations. 17,z*-z6
Humoral system defects result in an absence of
opsonization, an absence ofcomplement formation,
and an absence of T cells, while cellular-system
defects adversely affect cytotoxic T cells, lympho-
kine production, and phagocytosis or the presenta-
tion of antigens. Thus, an answer regarding the
relationship of cause and effect in candida infec-
tions will remain a mystery for some time: "In some
instances, however, the cause and effect relation-
ship is not clear, i.e., did the infection with candida
initiate the immunosuppression, or did the underly-
ing condition result in immunosuppression allowing
for candida to initiate disease? ’’z7
Immunostimulation by Means of Thymopentin
Although the slgA in the cervicovaginal secretions
could essentially be increased by thymopentin,
1
the therapeutic results could not be improved. This
observation emphasizes the importance ofthe cellu-
lar component with regard to resistance in vaginal
mycoses. The proliferation tests in vitro revealed
different reactions to candida antigens, depending
on the individual patient.
Mathur et al.z8 observed, in women with chronic
vaginal candidosis, normal reactions to PHA, which
is more stimulating to T-helper cells, but only weak
reactions to Con A, which is more stimulating to
the T-suppressor cytotoxic cells. There was a signif-
icant correlation between the depression and high
anti-candida antibody titers in the serum. Witkin
et al., z9 as we did, found no differences between
women with and without vaginal candidosis con-
cerning normal T-cell proliferation to mitogens, but
a weak response to candida antigen. The sera of
these patients suppressed the proliferation of con-
trol T lymphocytes against candida antigen.
Two reaction types were apparent in our patient
group. One group ofwomen with their numbers of
lymphocytes lying primarily within the middle or
upper normal range who, after candida and thymo-
pentin stimulation in vitro, revealed no increased
proliferations, although the unspecific mitogen
stimulation was normal and the lymphocytes after
thymopentin application in vivo were rather de-
creased. These women, in most cases, were not
cured from chronically relapsing vaginal candidosis.
Another group consisted ofwomen presenting with
primarily low numbers of T lymphocytes, which
could be increased by thymopentin and well stimu-
lated in vitro by candida antigen and thymopentin.
These women were cured.
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